Susanne Cabrera MD

Board Certifications: American Board of Pediatrics, American Board of Internal Medicine

Education

MD, University of Tennessee Health Science Center, 2005
Residency, Internal Medicine and Pediatrics, Indiana University, Indianapolis, IN, 2009
Fellowship, Pediatric Endocrinology, Indiana University, Indianapolis, IN, 2011

The accurate prediction of type 1 diabetes occurrence by combining markers of beta cell dysfunction with heightened pro-inflammatory profiles

The overall goal of my research is to better predict those at risk of developing type 1 diabetes by combining early markers of beta cell dysfunction with specific pro-inflammatory profiles seen in those both progressing to T1D and in family members of those already affected with T1D, ultimately translating this mechanistic knowledge into clinical trials aimed at preventing T1D. This work builds off the existing and extensive research on molecular signatures in the longitudinal bio-bank of those affected with T1D and their family members by the McGee Center. Analysis of the inflammatory profiles of those progressing to T1D reveals a distinctive and predictive profile highlighted by a loss of regulation and a movement towards heightened inflammation. To improve these signatures as a predictive tool, I hope to link evidence of early beta cell dysfunction to the immune dysregulation. My hypothesis is that innate beta cell dysfunction is a necessary and critical for advancing this inflammation forward to clinical overt T1D.

I was fortunate to work in the lab of Dr. Raghu Mirmira, a beta cell biologist and physician-scientist, during my fellowship training in pediatric endocrinology at Indiana University. There, I researched the combined beta-cell and immune effects of several drugs in the non-obese diabetic mouse (a model of type 1 diabetes). This experience was critical in allowing me to bridge the gap between beta cell dysfunction and the immune response in T1D pathogenesis. Indeed, since joining the faculty at MCW, I have been active in the McGee Center investigating evidence of beta cell dysfunction in both low and high risk family members of those with T1D.

I am also researching the effect of a low antigen diet on decreasing gut hyper-permeability, systemic inflammation, and thus protecting beta cell function in the bio-breeding rat (a model of T1D). We believe endotoxin is a key player in driving the inflammatory response seen in those at risk of T1D, and that endotoxin exposure can be reduced by decreasing gut hyperpermeability through a low antigen diet. Early results suggest the decrease in gut hyperpermeability results in improved beta cell function.

Clinically, I am involved with the TrialNet Natural History study and the McGee Center’s Genetics of Autoimmunity in Type 1 Diabetes Mellitus, a longitudinal study of family members of those affected by T1D. My on-going clinical obligations to children and teens with T1D provide a wealth of potential subjects for recruitment (> 200 children are newly diagnosed through our Diabetes Center at MCW annually, over 1700 patients with T1D cared for in our Diabetes Clinic), and a valuable understanding of the morbidity associated with T1D. I am also a Clinical Research Scholar through the CTSI at MCW, an NIH supported program aimed at advancing the research careers of young investigators by securing extramural funding and providing a supportive framework.